Lyell Immunopharma, Inc. (LYEL)

Market Cap	584.42M
Revenue (ttm)	130,000
Net Income (ttm)	-234.63M
Shares Out	254.10M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	756,929
Open	2.420
Previous Close	2.440
Day's Range	2.290 - 2.480
52-Week Range	1.320 - 3.970
Beta	-0.56
Analysts	Buy
Price Target	5.50 (+139.13%)
Earnings Date	May 2, 2024

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epige...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 224
• Stock Exchange: NASDAQ
• Ticker Symbol: LYEL

Financial Performance

In 2023, LYEL's revenue was $130,000, a decrease of -99.85% compared to the previous year's $84.68 million. Losses were -$234.63 million, 28.1% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for LYEL stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 139.13% from the latest price.

Price Target

$5.5

(139.13% upside)

Analyst Consensus: Buy